EP0285287A3 — 3-benzazepine compounds for use in treating gastrointestinal motility disorders

USPTO Abstract

The use of a compound of the formula (I) : or a pharmaceutically acceptable acid addition salt thereof, in the manufacture of a medicament for the treatment of gastrointestinal motility disorders is described wherein R¹ is hydrogen, C₁-C₆ alkyl or C₃-C₅ alkenyl; R² is hydrogen, halogen, CF₃, C₁-C₆ alkyl or R⁴O; R³ is halogen, CF₃, C₁-C₆ alkyl, hydroxy, C₁-C₆ alkoxy,. S-(C₁-C₆) alkyl, S-trifluoro­ methyl, NO₂, SO n -phenyl where the phenyl is optionally substituted by hydroxy, C₁-C₆ alkoxy, halogen, CF₃, C₁-C₆ alkyl, SO n (C₁-C₆) alkyl, SO n CF₃, SO n -phenyl or SO₂NR⁵R⁶; R⁴ is hydrogen, C₁-C₆ alkyl, or C₁-C₆alkanoyl; R⁵ and R⁶ are hydrogen or C₁-C₆ alkyl; and n is 0, 1 or 2; provided R² is not hydrogen when R³ is S-phenyl in the 6-position and provided that when R² is hydroxy in the 8-position and R¹ is C₁-C₆ alkyl, R³ may be halogen or CF₃ only if it is in the 6-­ or 9-position.